The facility will be purpose-built with GMP (Goods Manufacturing Practice) readiness at its core. It will house cutting-edge technologies with scalable bioreactors designed for large-volume, clinical-grade viral vector production. These aren’t just upgrades, they’re the necessary tools to meet the moment biotech is in.
Full Article: linkedin.com